Objective To analyze the short-term efficacy of tiotropium bromide （Spiriva） combined with budesonide and formoterol fumarate dihydrate （Symbicort） in bronchial asthma-COPD overlap syndrome. Methods A total of 152 patients with bronchial asthma-COPD overlap syndrome were selected and divided into test group （80 cases） and control group （72 cases）. Test group patients took treatment of Spiriva combined with Symbicort based on regular treatment, control group patients adopted mucosotvan sheet and seretide treatment for four weeks. Treatment effect of patients was compared between two groups. Results After treatment,the lung function was improved in both groups of patients. The indexes of forced expiratory volume in one second （FEV1） and forced expiratory volume in one second occupation force vital capacity （FEV1/FVC） in test group were significantly higher than in control group （ P〈 0.05） ; the index of residual volume/total lung capacity （RV/TLC） in test group was significantly lower than that in control group （ P 〈0.05）. The COPD score （CAT score） was decreased in both groups, and was significantly lower in test group than in control group （ P〈0.05）. The asthma control test scores （CAT score） was increased in both groups and was significantly higher in test group than in control group （23±4 vs 15±2, P 〈0. 05）. The number of exacerbation was decreased in both groups and was significantly lower in test group than in control group. No severe adverse reaction occurred in both groups. There was no significant difference in the average cost between test group and control group （ P ±0.05）. Conclusion In patients with bronchial asthma-COPD overlap syndrome, Spiriva combined with Symbicort inhalation can improve the efficacy and cost of treatment did not significantly increase.